[adrotate group="3"]The platform will also include project management tools meant to propitiate an easier d
The Alzheimer's Drug Discovery Foundation (ADDF) and the Boston-based software company OnDeckBiotech are launching a new open access platform with the purpose of creating an improved way to connect scientists with a virtual network of contract research organizations (CROs), drug development experts, and educational resources. The announcement was made on third day of the ADDF's 15th International Conference on Alzheimer's Drug Discovery. The foundation is partnering with OnDeckBiotech in order to offer cutting-edge technology that helps to streamline links between researchers and CROs specializing in researching diseases of the central nervous system (CNS), as well as accelerating drug discovery research and development. ADDF ACCESS will offer "improved functionality, with enhanced search capabilities to help researchers identify companies that provide specific services relevant to CNS drug discovery and development," as explained by the foundation. The platform will also offer detailed profiles of featured CROs with information on platform technologies that may be important to CNS indications, opportunities to rate and review CROs, and a way of directly communicating with consultants and key personnel at CROs.